CLPT Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -69.31% compared to ClearPoint Neuro's net margin of 2.76%. ClearPoint Neuro's return on equity of -66.47% beat InfuSystems Holdings's return on equity of 4.33%.

ClearPoint Neuro has a consensus price target of $25.00, signalling upside risk potential of 117.01%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 183.64%. Given that InfuSystems Holdings has higher upside potential than ClearPoint Neuro, analysts believe InfuSystems Holdings is more attractive than ClearPoint Neuro.

ClearPoint Neuro has a beta of 0.974, which suggesting that the stock is 2.641% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.898, suggesting its more volatile than the S&P 500 by 89.81%.

ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

ClearPoint Neuro quarterly revenues are $7.8M, which are smaller than InfuSystems Holdings quarterly revenues of $33.8M. ClearPoint Neuro's net income of -$5.4M is lower than InfuSystems Holdings's net income of $933K. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 49.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 9.92x versus 0.80x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -69.31% compared to ClearPoint Neuro's net margin of -18.58%. ClearPoint Neuro's return on equity of -66.47% beat Retractable Technologies's return on equity of -16.83%.

ClearPoint Neuro has a consensus price target of $25.00, signalling upside risk potential of 117.01%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that ClearPoint Neuro has higher upside potential than Retractable Technologies, analysts believe ClearPoint Neuro is more attractive than Retractable Technologies.

ClearPoint Neuro has a beta of 0.974, which suggesting that the stock is 2.641% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

ClearPoint Neuro quarterly revenues are $7.8M, which are smaller than Retractable Technologies quarterly revenues of $10.3M. ClearPoint Neuro's net income of -$5.4M is lower than Retractable Technologies's net income of -$1.9M. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 9.92x versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -69.31% compared to ClearPoint Neuro's net margin of -1226.82%. ClearPoint Neuro's return on equity of -66.47% beat VolitionRX's return on equity of --.

ClearPoint Neuro has a consensus price target of $25.00, signalling upside risk potential of 117.01%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 484.8%. Given that VolitionRX has higher upside potential than ClearPoint Neuro, analysts believe VolitionRX is more attractive than ClearPoint Neuro.

ClearPoint Neuro has a beta of 0.974, which suggesting that the stock is 2.641% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

ClearPoint Neuro quarterly revenues are $7.8M, which are larger than VolitionRX quarterly revenues of $474.5K. ClearPoint Neuro's net income of -$5.4M is higher than VolitionRX's net income of -$5.8M. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 9.92x versus 35.08x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -69.31% compared to ClearPoint Neuro's net margin of -10.04%. ClearPoint Neuro's return on equity of -66.47% beat Xtant Medical Holdings's return on equity of -35.34%.

ClearPoint Neuro has a consensus price target of $25.00, signalling upside risk potential of 117.01%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 343.04%. Given that Xtant Medical Holdings has higher upside potential than ClearPoint Neuro, analysts believe Xtant Medical Holdings is more attractive than ClearPoint Neuro.

ClearPoint Neuro has a beta of 0.974, which suggesting that the stock is 2.641% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

ClearPoint Neuro quarterly revenues are $7.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. ClearPoint Neuro's net income of -$5.4M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 9.92x versus 0.45x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.